Stock comparison
LeMaitre Vascular
Theravance Biopharma
Scored across Buffett, Graham, Lynch and Greenblatt - plus a side-by-side metric table covering valuation, quality, growth and balance sheet.
LMAT
LeMaitre Vascular
Market cap
$2.23B
Sector
Healthcare
TBPH
Theravance Biopharma
Market cap
$843.92M
Sector
Healthcare
Overall winner
LeMaitre Vascular LMAT
Wins on the combined sum of fit scores across all four strategies. Per-strategy breakdown below.
Fit scores by strategy
| Strategy | LMAT | TBPH | Winner |
|---|---|---|---|
| Warren Buffett | 77B | 53D | LMAT |
| Benjamin Graham | 89A | 51D | LMAT |
| Philip Fisher | 81C | 45D | LMAT |
| Peter Lynch | 67B | 53C | LMAT |
| Joel Greenblatt | 56D | 36D | LMAT |
| Charlie Munger | 68D | 39D | LMAT |
| Terry Smith | 69D | 56C | LMAT |
Side-by-side metrics
| Metric | LMAT | TBPH |
|---|---|---|
| Market cap | $2.23B | $843.92M |
| P/E (TTM) | 37.1x | 7.4x |
| EV/EBIT | 36.6x | - |
| ROIC (TTM) | 9.43% | -1.32% |
| Gross margin | 72.39% | 104.1% |
| Net margin | 24.35% | 104.34% |
| Revenue CAGR 5y | 12.75% | 18.06% |
| EPS CAGR 5y | 19.04% | - |
| Debt / Equity | 0.5x | 0.3x |
| Dividend yield | 0.84% | 0.0% |
Where each one wins
The metrics with the biggest gap between the two - sorted so the most decisive edges read first.
LMAT leads on
- ROIC (TTM)9.43%vs -1.32%+114%
- Dividend yield0.84%vs 0.0%+100%
- Market cap$2.23Bvs $843.92M+62%
TBPH leads on
- EV/EBIT-vs 36.6x+177%
- P/E (TTM)7.4xvs 37.1x+80%
- Net margin104.34%vs 24.35%+77%
- Debt / Equity0.3xvs 0.5x+46%
Related on invest-like
Key terms in this analysis
Educational tool. Fit scores are deterministic projections from public financials onto each investor's published criteria - not personal recommendations or advice.